Drug Database
IN

influenza HA vaccine

✓ Approved

Denka Seiken · · Vaccine

What is influenza HA vaccine?

influenza HA vaccine is a vaccine developed by Denka Seiken. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

CompanyDenka Seiken
Drug ClassVaccine, Large Molecules
Molecular Target,
RouteInjectable (Others), Subcutaneous Injection
StatusApproved

Mechanism of Action

Molecular Targets

influenza HA vaccine acts on 2 molecular targets:

(HA)
(HA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Related Research Articles

PubMedNPJ vaccines2026-11-11

A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.

Liu Jia J, Chen Longping L, Li Dan D, Wang Zhuo Z et al.

Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.

PubMedCell death & disease2026-11-11

MASP1‑METTL3‑HAS2 axis aggravates liver fibrosis through HMW‑HA‑mediated senescence inhibition and LMW‑HA‑induced activation of hepatic stellate cells.

Liu Xianzhi X, Wang Peng P, Zeng Wei W, Liu Huajie H et al.

The hepatic microenvironment undergoes dynamic remodelling in advanced liver fibrosis. Hyaluronic acid (HA), a key component of this fibrotic microenvironment, plays a key role in disease progression. While cellular senescence is one of the fates that activated HSCs undergo and is associated with fibrosis resolution, the relationship between HA and HSC senescence in advanced liver fibrosis remains unclear. This study aimed to elucidate the specific mechanisms by which HA regulates HSC senescence. Here, intrahepatic HSC transplantation confirmed that an advanced fibrotic microenvironment inhibited HSC senescence and led to its sustained activation. Mechanistically, low-molecular-weight (LMW) HA promotes HSC activation via the CD44-p38-ATF2 axis, while HMW-HA simultaneously inhibits HSC senescence through the TLR4-SerpinE1 axis. Furthermore, HA synthesis is mediated by MASP1. MASP1 enhances the m6A methylation of HAS2 via METTL3, leading to increased HAS2 mRNA levels and consequently elevated HMW-HA synthesis, and HYAL2 mediates the conversion of HMW‑HA to LMW‑HA. Targeted knockdown of MASP1 in the liver reversed HA metabolism, subsequently promoting HSC senescence and alleviating liver fibrosis. Therefore, targeting HA metabolism to induce HSC senescence for activated HSC removal may represent a novel therapeutic strategy for liver fibrosis.

PubMedBMC oral health2026-11-11

Histological and histomorphometric effects of hyaluronic acid with or without xenograft on rat extraction socket healing.

Habib Aliaa A AA, Salem Eman M EM

Alveolar bone loss following tooth extraction remains a major clinical concern that may compromise future implant placement and prosthetic rehabilitation. Hyaluronic acid (HA), a natural component of the extracellular matrix, exhibits anti-inflammatory, angiogenic, and osteogenic properties that may enhance post-extraction healing. This experimental study evaluated the effect of HA, used alone or combined with a xenograft, on bone regeneration in extraction sockets. Twenty adult female Sprague-Dawley rats were included. Two animals served as untreated baseline histological references, while the remaining eighteen rats underwent mandibular first molar extraction and were randomly allocated into three groups (n = 6/group): extraction only (control), HA application, and HA combined with xenograft. Each group was further evaluated at 2, 4, and 6 weeks post-extraction, with two animals assessed at each healing interval. Histological evaluation was performed using hematoxylin and eosin (H&E) and Masson's trichrome staining. Histomorphometric analysis quantified the percentage of newly formed bone area within standardized regions of interest using calibrated ImageJ software. Differences among treatment groups were analyzed separately at each healing interval using one-way ANOVA or the Kruskal-Wallis test, as appropriate, followed by appropriate post-hoc multiple comparisons. Statistical significance was set at p < 0.05. Both HA-treated groups demonstrated significantly greater bone formation compared with extraction alone at all healing intervals (p < 0.001). Histological assessment revealed reduced inflammatory infiltrate and more organized trabecular architecture in HA-treated sockets. Masson's trichrome staining demonstrated increased collagen deposition and matrix organization, particularly in the HA + xenograft group. Although the combination therapy demonstrated numerically higher bone area values throughout the healing period, no statistically significant difference was observed between HA alone and HA combined with xenograft (p > 0.05). Within the limitations of this exploratory pilot animal study, HA significantly enhanced extraction socket healing by promoting new bone formation, improving trabecular organization, and increasing collagen deposition compared with spontaneous healing. The addition of xenograft resulted in slightly higher histological and histomorphometric values; however, it did not result in statistically superior bone formation compared with HA alone within the experimental timeframe. These findings suggest that HA may represent a promising adjunctive biomaterial for alveolar ridge preservation. Nevertheless, larger preclinical studies and well-designed randomized clinical trials are required to validate these findings and determine their clinical applicability. The adjunctive application of hyaluronic acid (HA), with or without bone substitute materials, may enhance post-extraction bone quality and accelerate healing dynamics. This could support more predictable ridge preservation outcomes and potentially facilitate early implant placement by improving the quantity and quality of newly formed bone. Therefore, HA may represent a clinically relevant biomaterial in contemporary alveolar ridge preservation protocols.

PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-11-11

People With Influenza Requiring ICU Admission During the 2025-2026 Season, Marked by the Emergence of Influenza A(H3N2) Subclade K: A French Prospective Nationwide Cohort Study.

de Prost Nicolas N, Bay Pierre P, Le Goff Marie M, Préau Sébastien S et al.

Intense influenza activity has been reported alongside the emergence of influenza A(H3N2) subclade K. While epidemiological studies have reported heterogeneous findings regarding public health impact, data remain lacking on its impact on clinical phenotype of people requiring intensive care unit (ICU) admission. Prospective, multicenter, observational SEVARVIR cohort study including people admitted in 42 French ICUs with laboratory-confirmed influenza infection during the 2024-2025 and 2025-2026 seasons. Primary end point was day-28 mortality. Seven hundred twenty-six people were admitted for influenza in 2024-2025 (n = 360) and 2025-2026 (n = 366). In 2025-2026, influenza subtype was available for 265 people; 49% (n = 129) had A(H1N1)pdm09 and 51% (n = 136) had A(H3N2) subtype infection. Among the 40 people with A(H3N2) infection for whom whole-genome sequencing was available, 33 (82.5%) belonged to subclade K. In multivariable Cox analysis of the 2025-2026 season, age (adjusted hazard ratio, aHR = 1.04 [1.01;1.09]; P = .015), Clinical Frailty Scale (aHR = 1.59 [1.28;1.98]; P < .001), and sequential organ failure assessment score (aHR = 1.15 [1.05;1.26]; P = .003) were associated with an increased risk of death. In the 2024-2025/2025-2026 seasons or 2025-2026 season alone, influenza subtype was not associated with a significant risk of day-28 mortality. Phylogenetic analyses from our ICU cohort together with 600 contextual sequences from community-acquired influenza cases collected during the period showed no clustering according to severity. There was no evidence of an increased risk of death among critically ill people with influenza during the 2025-2026 season, despite the emergence of influenza A(H3N2) subclade K. NCT05162508.

PubMedJournal of sleep research2026-11-11

2010 and 2013 Incidence Peaks in Narcolepsy and Idiopathic Hypersomnia Linked to Type A H1N1 and Type B Victoria Influenza Strains.

Zhang Zhongxing Z, Gool Jari K JK, Sirotkin Pavel P, Dauvilliers Yves Y et al.

Increased narcolepsy type-1 (NT1) incidence rates were reported globally in 2010, linked to the H1N1 2009-2010 influenza pandemic and Pandemrix vaccination. A child-specific NT1 peak was observed in Europe in 2013, further raising questions about the relationship between NT1 and influenza infections. This study analysed annual European incidence patterns of central disorders of hypersomnolence (CDH) in relation to influenza severity. All NT1 (N = 981) and a combined group of narcolepsy type-2 (NT2) and idiopathic hypersomnia (IH) (N = 545) cases from eight European centers were studied from 1995 to 2019. Linear mixed models and Spearman correlations were applied to investigate the relationships between CDH incidence and the severity of preceding influenza seasons, including H1N1, H3N2, and for the Netherlands, influenza Type B Victoria and Yamagata. Peaks in NT1 incidence were present in 2010 and 2013, while a 2010 child-specific peak was identified in NT2 and IH. Both groups showed a significantly positive correlation with H1N1 influenza severity and a negative correlation with H3N2. NT1 was also significantly associated with influenza Type B Victoria in the Netherlands, particularly in children. These findings suggest that, beyond H1N1, influenza Type B Victoria may be a novel trigger for NT1. Similar to NT1, the 2010 children peak in NT2 and IH may indicate possible immune-related pathophysiologies linked to the 2009-2010 H1N1 pandemic. Further immunological studies are warranted to unravel the complexities of these relationships and their implications for CDH.

PubMedJournal of agricultural and food chemistry2026-11-11

Discovery of Novel Endolytic Hyaluronate Lyases Belonging to a New Subfamily of GH56 and Enhancement of Catalytic Activity through Catalytic Cleft Engineering.

Yu Xiangfan X, Jing Yiwen Y, Liu Lei L, Ma Zhenyu Z et al.

Hyaluronate lyases have been widely used to degrade hyaluronic acid (HA) and prepare HA oligosaccharides. To date, no hyaluronate lyase has been reported in glycoside hydrolase family 56 (GH56). Herein, SpskHL from Sporothrix schenckii 1099-18 was first identified as a GH56 endolytic hyaluronate lyase, and then its four homologues were discovered. These five microbial GH56 enzymes cleaved HA, yielding unsaturated HA oligosaccharides with ΔHA2 as the end product, forming a new GH56 subfamily of endolytic hyaluronate lyase. Through alanine-scanning mutagenesis of 15 residues in the catalytic cleft of SpskHL and combining three positive mutations, triple-site mutant SpskHLM3 (Y120A/N125A/H189A) increased activity by 126%. Grafting of the triple-site mutation onto four other hyaluronate lyases increased their activities by 74%-155%. Molecular dynamics simulations suggested that all five triple-site mutants had an expanded catalytic cleft, a larger cavity near the catalytic residue E, and a shorter catalytic OE2-O4 distance, which might contribute to their enhanced activities.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about influenza HA vaccine